Neuropsychiatric complications and associated management in adolescent and young adult cancer survivors: An All of Us study

Abstract

AbstractBackgroundAbout 4.5% of new cancer cases affect adolescent and young adult aged between 15 and 39 years in the United States (US). However, the effect of neuropsychiatric conditions on long‐term adolescent and young adult cancer (AYAC) survivors has not been formally investigated. Thus, the impact and management of late neuropsychiatric complications in AYAC survivors compared to non‐cancer‐matched controls (NCMC) in the US were evaluated using the All of Us (AoU) Research Program.MethodsParticipants in the AoU Controlled Tier Dataset (v6) diagnosed with cancer between ages 15 and 39 were identified from electronic health records and surveys. AYAC survivors were matched with NCMC using the optimal pair‐matching algorithm at a 1:4 ratio. Data on past diagnoses, current follow‐up care, and treatment patterns of neuropsychiatric complications were collected.ResultsAnalysis was performed on 788 AYAC survivors and 3152 NCMC. AYAC survivors, with an average of 8.8 years since their first cancer diagnosis, were more likely than NCMC to receive a diagnosis of neuropathy, memory loss and epilepsy (p  < 0.001). Survivors also had a higher rate of follow‐up care and treatment utilization for these neurological conditions compared to NCMC (p  < 0.05). Treatment utilization was highest among survivors receiving care for epilepsy (88%), and lower for neuropathy (70%), memory loss (61%), and chronic fatigue (59%).ConclusionsThis large study reveals that AYAC survivors, on average 9 years after their cancer diagnosis, require more frequent follow‐up care for neurological complications compared to non‐cancer individuals. However, the management of neuropathy, memory loss, and chronic fatigue is hindered by a lack of mechanism‐based effective therapies.